Quent Capital, LLC Halozyme Therapeutics, Inc. Transaction History
Quent Capital, LLC
- $882 Million
- Q2 2024
A detailed history of Quent Capital, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Quent Capital, LLC holds 105 shares of HALO stock, worth $6,397. This represents 0.0% of its overall portfolio holdings.
Number of Shares
105
Previous 105
-0.0%
Holding current value
$6,397
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
489Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.07 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$785 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$354 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$246 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$226 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.49B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...